Modulating RNA splicing can augment antitumor T-cell responses (by Srosenbe via Wikimedia Commons)

Altered RNA splicing in cancer cells can give rise to neoantigens, but it is unclear whether this is clinically relevant and therapeutically targetable. Using B16-F10 and MC38 tumor models, Lu et al. find several compounds that modulate RNA splicing can inhibit tumor growth and improve responses to anti-PD1 checkpoint blockade. These effects are dependent on T cells and MHC class I peptide presentation. Neoepitopes induced by pharmacologic modulation of RNA splicing in B16-F10 cells can trigger antitumor T-cell responses in mice. The data suggest potential new approaches to enhancing cancer immunotherapy.

Lu SX, …, Bradley RK. Cell 2021 Jul 22;184:4032–47.e31.

Arming CAR T cells with BATF enhances efficacy (from Spezadams via Wikimedia Commons)

The transcriptional networks underlying T-cell exhaustion, including exhaustion in CAR T cells, are not fully known. Seo et al. show that basic leucine...

You do not currently have access to this content.